PoplarV1, Main, Exploration, bibRecord, 001C19

Olanzapine or chlorpromazine plus lithium in first episode psychotic mania: An 8-week randomised controlled trial.

Identifieur interne : 001C19 ( Main/Exploration ); précédent : 001C18; suivant : 001C20

Olanzapine or chlorpromazine plus lithium in first episode psychotic mania: An 8-week randomised controlled trial.

Auteurs : P. Conus [Australie] ; M. Berk [Australie] ; S M Cotton [Australie] ; L. Kader [Australie] ; C. Macneil [Australie] ; M K Hasty [Australie] ; K. Hallam [Australie] ; M. Lambert [Allemagne] ; B P Murphy [Australie] ; P D Mcgorry [Australie]

Source :

European psychiatry : the journal of the Association of European Psychiatrists [ 1778-3585 ] ; 2015.

RBID : pubmed:26485297

Descripteurs français

KwdFr :
- Adulte (MeSH), Benzodiazépines (administration et posologie), Benzodiazépines (effets indésirables), Chlorpromazine (administration et posologie), Chlorpromazine (effets indésirables), Diagnostic and stastistical manual of mental disorders (USA) (MeSH), Femelle (MeSH), Humains (MeSH), Lithium (usage thérapeutique), Mâle (MeSH), Neuroleptiques (administration et posologie), Neuroleptiques (effets indésirables), Olanzapine (MeSH), Résultat thérapeutique (MeSH), Surveillance des médicaments (MeSH), Trouble bipolaire (diagnostic), Trouble bipolaire (psychologie), Trouble bipolaire (traitement médicamenteux), Troubles psychotiques (traitement médicamenteux).
MESH :
- administration et posologie : Benzodiazépines, Chlorpromazine, Neuroleptiques.
- diagnostic : Trouble bipolaire.
- effets indésirables : Benzodiazépines, Chlorpromazine, Neuroleptiques.
- psychologie : Trouble bipolaire.
- traitement médicamenteux : Trouble bipolaire, Troubles psychotiques.
- usage thérapeutique : Lithium.
- Adulte, Diagnostic and stastistical manual of mental disorders (USA), Femelle, Humains, Mâle, Olanzapine, Résultat thérapeutique, Surveillance des médicaments.

English descriptors

KwdEn :
- Adult (MeSH), Antipsychotic Agents (administration & dosage), Antipsychotic Agents (adverse effects), Benzodiazepines (administration & dosage), Benzodiazepines (adverse effects), Bipolar Disorder (diagnosis), Bipolar Disorder (drug therapy), Bipolar Disorder (psychology), Chlorpromazine (administration & dosage), Chlorpromazine (adverse effects), Diagnostic and Statistical Manual of Mental Disorders (MeSH), Drug Monitoring (MeSH), Female (MeSH), Humans (MeSH), Lithium (therapeutic use), Male (MeSH), Olanzapine (MeSH), Psychotic Disorders (drug therapy), Treatment Outcome (MeSH).
MESH :
- chemical , administration & dosage : Antipsychotic Agents, Benzodiazepines, Chlorpromazine.
- chemical , adverse effects : Antipsychotic Agents, Benzodiazepines, Chlorpromazine.
- diagnosis : Bipolar Disorder.
- drug therapy : Bipolar Disorder, Psychotic Disorders.
- psychology : Bipolar Disorder.
- chemical , therapeutic use : Lithium.
- Adult, Diagnostic and Statistical Manual of Mental Disorders, Drug Monitoring, Female, Humans, Male, Olanzapine, Treatment Outcome.

Abstract

BACKGROUND

Treatment strategies for mental disorders may vary according to illness stage. However no data currently exist to guide treatment in first episode psychotic mania. The aim of this study was to compare the safety and efficacy profile of chlorpromazine and olanzapine, as add-on to lithium, in patients with a first episode of psychotic mania, expecting better safety profile and adherence to olanzapine but similar efficacy for both treatments.

METHODS

Data from 83 patients were collected in an 8-week randomised controlled trial on clinical variables, side effects, vital signs, and weight. Analyses of treatment differences over time were based on intent-to-treat principles. Kaplan-Meier estimated survival curves were used to analyse time-to-event data and mixed effects models repeated measures analysis of variance were used to determine treatment group differences over time on safety and efficacy measures.

RESULTS

Ethics committee approval to delay informed consent procedure until recovery from the acute episode allowed the inclusion of 83 patients highly representative of those treated in the public sector. Contrary to our hypotheses, safety profile of both medications was similar. A signal for higher rate (P=.032) and earlier occurrence (P=.043) of mania remission was observed in the olanzapine group which did not survive correction for multiple comparisons.

CONCLUSIONS

Olanzapine and chlorpromazine have a similar safety profile in a uniquely representative cohort of patients with first episode psychotic mania. The possibility for a greater impact of olanzapine on manic symptoms leading to earlier remission of the episode needs exploration in a large sample.

DOI: 10.1016/j.eurpsy.2015.09.009
PubMed: 26485297

Affiliations:

Links toward previous steps (curation, corpus...)

to stream Main, to step Corpus: 001A67
to stream Main, to step Curation: 001A67

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Olanzapine or chlorpromazine plus lithium in first episode psychotic mania: An 8-week randomised controlled trial.</title>
<author><name sortKey="Conus, P" sort="Conus, P" uniqKey="Conus P" first="P" last="Conus">P. Conus</name>
<affiliation wicri:level="4"><nlm:affiliation>Treatment and Early Intervention in Psychosis Program (TIPP), département de psychiatrie CHUV, université de Lausanne, clinique de Cery, 1008 Prilly, Switzerland; Orygen Youth Health Research Centre, Centre for Youth Mental Health, University of Melbourne, 35 Poplar Road, Parkville Victoria 3052, Melbourne, Australia. Electronic address: philippe.conus@chuv.ch.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Treatment and Early Intervention in Psychosis Program (TIPP), département de psychiatrie CHUV, université de Lausanne, clinique de Cery, 1008 Prilly, Switzerland; Orygen Youth Health Research Centre, Centre for Youth Mental Health, University of Melbourne, 35 Poplar Road, Parkville Victoria 3052, Melbourne</wicri:regionArea>
<placeName><settlement type="city">Melbourne</settlement>
<region type="état">Victoria (État)</region>
</placeName>
<orgName type="university">Université de Melbourne</orgName>
</affiliation>
</author>
<author><name sortKey="Berk, M" sort="Berk, M" uniqKey="Berk M" first="M" last="Berk">M. Berk</name>
<affiliation wicri:level="4"><nlm:affiliation>Orygen Youth Health Research Centre, Centre for Youth Mental Health, University of Melbourne, 35 Poplar Road, Parkville Victoria 3052, Melbourne, Australia; Department of Clinical and Biomedical Sciences, Barwon Health, University of Melbourne, Geelong, Australia; Mental Health Research Institute, Parkville, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Orygen Youth Health Research Centre, Centre for Youth Mental Health, University of Melbourne, 35 Poplar Road, Parkville Victoria 3052, Melbourne, Australia; Department of Clinical and Biomedical Sciences, Barwon Health, University of Melbourne, Geelong, Australia; Mental Health Research Institute, Parkville</wicri:regionArea>
<orgName type="university">Université de Melbourne</orgName>
<placeName><settlement type="city">Melbourne</settlement>
<region type="état">Victoria (État)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Cotton, S M" sort="Cotton, S M" uniqKey="Cotton S" first="S M" last="Cotton">S M Cotton</name>
<affiliation wicri:level="4"><nlm:affiliation>Orygen Youth Health Research Centre, Centre for Youth Mental Health, University of Melbourne, 35 Poplar Road, Parkville Victoria 3052, Melbourne, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Orygen Youth Health Research Centre, Centre for Youth Mental Health, University of Melbourne, 35 Poplar Road, Parkville Victoria 3052, Melbourne</wicri:regionArea>
<placeName><settlement type="city">Melbourne</settlement>
<region type="état">Victoria (État)</region>
</placeName>
<orgName type="university">Université de Melbourne</orgName>
</affiliation>
</author>
<author><name sortKey="Kader, L" sort="Kader, L" uniqKey="Kader L" first="L" last="Kader">L. Kader</name>
<affiliation wicri:level="4"><nlm:affiliation>Orygen Youth Health Research Centre, Centre for Youth Mental Health, University of Melbourne, 35 Poplar Road, Parkville Victoria 3052, Melbourne, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Orygen Youth Health Research Centre, Centre for Youth Mental Health, University of Melbourne, 35 Poplar Road, Parkville Victoria 3052, Melbourne</wicri:regionArea>
<placeName><settlement type="city">Melbourne</settlement>
<region type="état">Victoria (État)</region>
</placeName>
<orgName type="university">Université de Melbourne</orgName>
</affiliation>
</author>
<author><name sortKey="Macneil, C" sort="Macneil, C" uniqKey="Macneil C" first="C" last="Macneil">C. Macneil</name>
<affiliation wicri:level="4"><nlm:affiliation>Orygen Youth Health Research Centre, Centre for Youth Mental Health, University of Melbourne, 35 Poplar Road, Parkville Victoria 3052, Melbourne, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Orygen Youth Health Research Centre, Centre for Youth Mental Health, University of Melbourne, 35 Poplar Road, Parkville Victoria 3052, Melbourne</wicri:regionArea>
<placeName><settlement type="city">Melbourne</settlement>
<region type="état">Victoria (État)</region>
</placeName>
<orgName type="university">Université de Melbourne</orgName>
</affiliation>
</author>
<author><name sortKey="Hasty, M K" sort="Hasty, M K" uniqKey="Hasty M" first="M K" last="Hasty">M K Hasty</name>
<affiliation wicri:level="4"><nlm:affiliation>Orygen Youth Health Research Centre, Centre for Youth Mental Health, University of Melbourne, 35 Poplar Road, Parkville Victoria 3052, Melbourne, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Orygen Youth Health Research Centre, Centre for Youth Mental Health, University of Melbourne, 35 Poplar Road, Parkville Victoria 3052, Melbourne</wicri:regionArea>
<placeName><settlement type="city">Melbourne</settlement>
<region type="état">Victoria (État)</region>
</placeName>
<orgName type="university">Université de Melbourne</orgName>
</affiliation>
</author>
<author><name sortKey="Hallam, K" sort="Hallam, K" uniqKey="Hallam K" first="K" last="Hallam">K. Hallam</name>
<affiliation wicri:level="4"><nlm:affiliation>Orygen Youth Health Research Centre, Centre for Youth Mental Health, University of Melbourne, 35 Poplar Road, Parkville Victoria 3052, Melbourne, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Orygen Youth Health Research Centre, Centre for Youth Mental Health, University of Melbourne, 35 Poplar Road, Parkville Victoria 3052, Melbourne</wicri:regionArea>
<placeName><settlement type="city">Melbourne</settlement>
<region type="état">Victoria (État)</region>
</placeName>
<orgName type="university">Université de Melbourne</orgName>
</affiliation>
</author>
<author><name sortKey="Lambert, M" sort="Lambert, M" uniqKey="Lambert M" first="M" last="Lambert">M. Lambert</name>
<affiliation wicri:level="3"><nlm:affiliation>Department for Psychiatry and Psychotherapy, Psychosis Early Detection and Intervention Centre (PEDIC), Centre for Psychosocial Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Department for Psychiatry and Psychotherapy, Psychosis Early Detection and Intervention Centre (PEDIC), Centre for Psychosocial Medicine, University Medical Center Hamburg-Eppendorf, Hamburg</wicri:regionArea>
<placeName><settlement type="city">Hambourg</settlement>
<region type="land" nuts="2">Hambourg</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Murphy, B P" sort="Murphy, B P" uniqKey="Murphy B" first="B P" last="Murphy">B P Murphy</name>
<affiliation wicri:level="1"><nlm:affiliation>Faculty of Medicine, Nursing and Health Sciences, School of Psychology, Psychiatry and Psychological Medicine, Monash University, Victoria 3800, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Faculty of Medicine, Nursing and Health Sciences, School of Psychology, Psychiatry and Psychological Medicine, Monash University, Victoria 3800</wicri:regionArea>
<wicri:noRegion>Victoria 3800</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Mcgorry, P D" sort="Mcgorry, P D" uniqKey="Mcgorry P" first="P D" last="Mcgorry">P D Mcgorry</name>
<affiliation wicri:level="4"><nlm:affiliation>Orygen Youth Health Research Centre, Centre for Youth Mental Health, University of Melbourne, 35 Poplar Road, Parkville Victoria 3052, Melbourne, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Orygen Youth Health Research Centre, Centre for Youth Mental Health, University of Melbourne, 35 Poplar Road, Parkville Victoria 3052, Melbourne</wicri:regionArea>
<placeName><settlement type="city">Melbourne</settlement>
<region type="état">Victoria (État)</region>
</placeName>
<orgName type="university">Université de Melbourne</orgName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2015">2015</date>
<idno type="RBID">pubmed:26485297</idno>
<idno type="pmid">26485297</idno>
<idno type="doi">10.1016/j.eurpsy.2015.09.009</idno>
<idno type="wicri:Area/Main/Corpus">001A67</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">001A67</idno>
<idno type="wicri:Area/Main/Curation">001A67</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">001A67</idno>
<idno type="wicri:Area/Main/Exploration">001A67</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Olanzapine or chlorpromazine plus lithium in first episode psychotic mania: An 8-week randomised controlled trial.</title>
<author><name sortKey="Conus, P" sort="Conus, P" uniqKey="Conus P" first="P" last="Conus">P. Conus</name>
<affiliation wicri:level="4"><nlm:affiliation>Treatment and Early Intervention in Psychosis Program (TIPP), département de psychiatrie CHUV, université de Lausanne, clinique de Cery, 1008 Prilly, Switzerland; Orygen Youth Health Research Centre, Centre for Youth Mental Health, University of Melbourne, 35 Poplar Road, Parkville Victoria 3052, Melbourne, Australia. Electronic address: philippe.conus@chuv.ch.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Treatment and Early Intervention in Psychosis Program (TIPP), département de psychiatrie CHUV, université de Lausanne, clinique de Cery, 1008 Prilly, Switzerland; Orygen Youth Health Research Centre, Centre for Youth Mental Health, University of Melbourne, 35 Poplar Road, Parkville Victoria 3052, Melbourne</wicri:regionArea>
<placeName><settlement type="city">Melbourne</settlement>
<region type="état">Victoria (État)</region>
</placeName>
<orgName type="university">Université de Melbourne</orgName>
</affiliation>
</author>
<author><name sortKey="Berk, M" sort="Berk, M" uniqKey="Berk M" first="M" last="Berk">M. Berk</name>
<affiliation wicri:level="4"><nlm:affiliation>Orygen Youth Health Research Centre, Centre for Youth Mental Health, University of Melbourne, 35 Poplar Road, Parkville Victoria 3052, Melbourne, Australia; Department of Clinical and Biomedical Sciences, Barwon Health, University of Melbourne, Geelong, Australia; Mental Health Research Institute, Parkville, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Orygen Youth Health Research Centre, Centre for Youth Mental Health, University of Melbourne, 35 Poplar Road, Parkville Victoria 3052, Melbourne, Australia; Department of Clinical and Biomedical Sciences, Barwon Health, University of Melbourne, Geelong, Australia; Mental Health Research Institute, Parkville</wicri:regionArea>
<orgName type="university">Université de Melbourne</orgName>
<placeName><settlement type="city">Melbourne</settlement>
<region type="état">Victoria (État)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Cotton, S M" sort="Cotton, S M" uniqKey="Cotton S" first="S M" last="Cotton">S M Cotton</name>
<affiliation wicri:level="4"><nlm:affiliation>Orygen Youth Health Research Centre, Centre for Youth Mental Health, University of Melbourne, 35 Poplar Road, Parkville Victoria 3052, Melbourne, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Orygen Youth Health Research Centre, Centre for Youth Mental Health, University of Melbourne, 35 Poplar Road, Parkville Victoria 3052, Melbourne</wicri:regionArea>
<placeName><settlement type="city">Melbourne</settlement>
<region type="état">Victoria (État)</region>
</placeName>
<orgName type="university">Université de Melbourne</orgName>
</affiliation>
</author>
<author><name sortKey="Kader, L" sort="Kader, L" uniqKey="Kader L" first="L" last="Kader">L. Kader</name>
<affiliation wicri:level="4"><nlm:affiliation>Orygen Youth Health Research Centre, Centre for Youth Mental Health, University of Melbourne, 35 Poplar Road, Parkville Victoria 3052, Melbourne, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Orygen Youth Health Research Centre, Centre for Youth Mental Health, University of Melbourne, 35 Poplar Road, Parkville Victoria 3052, Melbourne</wicri:regionArea>
<placeName><settlement type="city">Melbourne</settlement>
<region type="état">Victoria (État)</region>
</placeName>
<orgName type="university">Université de Melbourne</orgName>
</affiliation>
</author>
<author><name sortKey="Macneil, C" sort="Macneil, C" uniqKey="Macneil C" first="C" last="Macneil">C. Macneil</name>
<affiliation wicri:level="4"><nlm:affiliation>Orygen Youth Health Research Centre, Centre for Youth Mental Health, University of Melbourne, 35 Poplar Road, Parkville Victoria 3052, Melbourne, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Orygen Youth Health Research Centre, Centre for Youth Mental Health, University of Melbourne, 35 Poplar Road, Parkville Victoria 3052, Melbourne</wicri:regionArea>
<placeName><settlement type="city">Melbourne</settlement>
<region type="état">Victoria (État)</region>
</placeName>
<orgName type="university">Université de Melbourne</orgName>
</affiliation>
</author>
<author><name sortKey="Hasty, M K" sort="Hasty, M K" uniqKey="Hasty M" first="M K" last="Hasty">M K Hasty</name>
<affiliation wicri:level="4"><nlm:affiliation>Orygen Youth Health Research Centre, Centre for Youth Mental Health, University of Melbourne, 35 Poplar Road, Parkville Victoria 3052, Melbourne, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Orygen Youth Health Research Centre, Centre for Youth Mental Health, University of Melbourne, 35 Poplar Road, Parkville Victoria 3052, Melbourne</wicri:regionArea>
<placeName><settlement type="city">Melbourne</settlement>
<region type="état">Victoria (État)</region>
</placeName>
<orgName type="university">Université de Melbourne</orgName>
</affiliation>
</author>
<author><name sortKey="Hallam, K" sort="Hallam, K" uniqKey="Hallam K" first="K" last="Hallam">K. Hallam</name>
<affiliation wicri:level="4"><nlm:affiliation>Orygen Youth Health Research Centre, Centre for Youth Mental Health, University of Melbourne, 35 Poplar Road, Parkville Victoria 3052, Melbourne, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Orygen Youth Health Research Centre, Centre for Youth Mental Health, University of Melbourne, 35 Poplar Road, Parkville Victoria 3052, Melbourne</wicri:regionArea>
<placeName><settlement type="city">Melbourne</settlement>
<region type="état">Victoria (État)</region>
</placeName>
<orgName type="university">Université de Melbourne</orgName>
</affiliation>
</author>
<author><name sortKey="Lambert, M" sort="Lambert, M" uniqKey="Lambert M" first="M" last="Lambert">M. Lambert</name>
<affiliation wicri:level="3"><nlm:affiliation>Department for Psychiatry and Psychotherapy, Psychosis Early Detection and Intervention Centre (PEDIC), Centre for Psychosocial Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Department for Psychiatry and Psychotherapy, Psychosis Early Detection and Intervention Centre (PEDIC), Centre for Psychosocial Medicine, University Medical Center Hamburg-Eppendorf, Hamburg</wicri:regionArea>
<placeName><settlement type="city">Hambourg</settlement>
<region type="land" nuts="2">Hambourg</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Murphy, B P" sort="Murphy, B P" uniqKey="Murphy B" first="B P" last="Murphy">B P Murphy</name>
<affiliation wicri:level="1"><nlm:affiliation>Faculty of Medicine, Nursing and Health Sciences, School of Psychology, Psychiatry and Psychological Medicine, Monash University, Victoria 3800, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Faculty of Medicine, Nursing and Health Sciences, School of Psychology, Psychiatry and Psychological Medicine, Monash University, Victoria 3800</wicri:regionArea>
<wicri:noRegion>Victoria 3800</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Mcgorry, P D" sort="Mcgorry, P D" uniqKey="Mcgorry P" first="P D" last="Mcgorry">P D Mcgorry</name>
<affiliation wicri:level="4"><nlm:affiliation>Orygen Youth Health Research Centre, Centre for Youth Mental Health, University of Melbourne, 35 Poplar Road, Parkville Victoria 3052, Melbourne, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Orygen Youth Health Research Centre, Centre for Youth Mental Health, University of Melbourne, 35 Poplar Road, Parkville Victoria 3052, Melbourne</wicri:regionArea>
<placeName><settlement type="city">Melbourne</settlement>
<region type="état">Victoria (État)</region>
</placeName>
<orgName type="university">Université de Melbourne</orgName>
</affiliation>
</author>
</analytic>
<series><title level="j">European psychiatry : the journal of the Association of European Psychiatrists</title>
<idno type="eISSN">1778-3585</idno>
<imprint><date when="2015" type="published">2015</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult (MeSH)</term>
<term>Antipsychotic Agents (administration & dosage)</term>
<term>Antipsychotic Agents (adverse effects)</term>
<term>Benzodiazepines (administration & dosage)</term>
<term>Benzodiazepines (adverse effects)</term>
<term>Bipolar Disorder (diagnosis)</term>
<term>Bipolar Disorder (drug therapy)</term>
<term>Bipolar Disorder (psychology)</term>
<term>Chlorpromazine (administration & dosage)</term>
<term>Chlorpromazine (adverse effects)</term>
<term>Diagnostic and Statistical Manual of Mental Disorders (MeSH)</term>
<term>Drug Monitoring (MeSH)</term>
<term>Female (MeSH)</term>
<term>Humans (MeSH)</term>
<term>Lithium (therapeutic use)</term>
<term>Male (MeSH)</term>
<term>Olanzapine (MeSH)</term>
<term>Psychotic Disorders (drug therapy)</term>
<term>Treatment Outcome (MeSH)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Adulte (MeSH)</term>
<term>Benzodiazépines (administration et posologie)</term>
<term>Benzodiazépines (effets indésirables)</term>
<term>Chlorpromazine (administration et posologie)</term>
<term>Chlorpromazine (effets indésirables)</term>
<term>Diagnostic and stastistical manual of mental disorders (USA) (MeSH)</term>
<term>Femelle (MeSH)</term>
<term>Humains (MeSH)</term>
<term>Lithium (usage thérapeutique)</term>
<term>Mâle (MeSH)</term>
<term>Neuroleptiques (administration et posologie)</term>
<term>Neuroleptiques (effets indésirables)</term>
<term>Olanzapine (MeSH)</term>
<term>Résultat thérapeutique (MeSH)</term>
<term>Surveillance des médicaments (MeSH)</term>
<term>Trouble bipolaire (diagnostic)</term>
<term>Trouble bipolaire (psychologie)</term>
<term>Trouble bipolaire (traitement médicamenteux)</term>
<term>Troubles psychotiques (traitement médicamenteux)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antipsychotic Agents</term>
<term>Benzodiazepines</term>
<term>Chlorpromazine</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antipsychotic Agents</term>
<term>Benzodiazepines</term>
<term>Chlorpromazine</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Benzodiazépines</term>
<term>Chlorpromazine</term>
<term>Neuroleptiques</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Bipolar Disorder</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnostic" xml:lang="fr"><term>Trouble bipolaire</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Bipolar Disorder</term>
<term>Psychotic Disorders</term>
</keywords>
<keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Benzodiazépines</term>
<term>Chlorpromazine</term>
<term>Neuroleptiques</term>
</keywords>
<keywords scheme="MESH" qualifier="psychologie" xml:lang="fr"><term>Trouble bipolaire</term>
</keywords>
<keywords scheme="MESH" qualifier="psychology" xml:lang="en"><term>Bipolar Disorder</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Lithium</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Trouble bipolaire</term>
<term>Troubles psychotiques</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Lithium</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adult</term>
<term>Diagnostic and Statistical Manual of Mental Disorders</term>
<term>Drug Monitoring</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Olanzapine</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Adulte</term>
<term>Diagnostic and stastistical manual of mental disorders (USA)</term>
<term>Femelle</term>
<term>Humains</term>
<term>Mâle</term>
<term>Olanzapine</term>
<term>Résultat thérapeutique</term>
<term>Surveillance des médicaments</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><p><b>BACKGROUND</b>
</p>
<p>Treatment strategies for mental disorders may vary according to illness stage. However no data currently exist to guide treatment in first episode psychotic mania. The aim of this study was to compare the safety and efficacy profile of chlorpromazine and olanzapine, as add-on to lithium, in patients with a first episode of psychotic mania, expecting better safety profile and adherence to olanzapine but similar efficacy for both treatments.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>METHODS</b>
</p>
<p>Data from 83 patients were collected in an 8-week randomised controlled trial on clinical variables, side effects, vital signs, and weight. Analyses of treatment differences over time were based on intent-to-treat principles. Kaplan-Meier estimated survival curves were used to analyse time-to-event data and mixed effects models repeated measures analysis of variance were used to determine treatment group differences over time on safety and efficacy measures.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>RESULTS</b>
</p>
<p>Ethics committee approval to delay informed consent procedure until recovery from the acute episode allowed the inclusion of 83 patients highly representative of those treated in the public sector. Contrary to our hypotheses, safety profile of both medications was similar. A signal for higher rate (P=.032) and earlier occurrence (P=.043) of mania remission was observed in the olanzapine group which did not survive correction for multiple comparisons.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>CONCLUSIONS</b>
</p>
<p>Olanzapine and chlorpromazine have a similar safety profile in a uniquely representative cohort of patients with first episode psychotic mania. The possibility for a greater impact of olanzapine on manic symptoms leading to earlier remission of the episode needs exploration in a large sample.</p>
</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">26485297</PMID>
<DateCompleted><Year>2016</Year>
<Month>06</Month>
<Day>27</Day>
</DateCompleted>
<DateRevised><Year>2020</Year>
<Month>01</Month>
<Day>09</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1778-3585</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>30</Volume>
<Issue>8</Issue>
<PubDate><Year>2015</Year>
<Month>Nov</Month>
</PubDate>
</JournalIssue>
<Title>European psychiatry : the journal of the Association of European Psychiatrists</Title>
<ISOAbbreviation>Eur Psychiatry</ISOAbbreviation>
</Journal>
<ArticleTitle>Olanzapine or chlorpromazine plus lithium in first episode psychotic mania: An 8-week randomised controlled trial.</ArticleTitle>
<Pagination><MedlinePgn>975-82</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.eurpsy.2015.09.009</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S0924-9338(15)00179-0</ELocationID>
<Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Treatment strategies for mental disorders may vary according to illness stage. However no data currently exist to guide treatment in first episode psychotic mania. The aim of this study was to compare the safety and efficacy profile of chlorpromazine and olanzapine, as add-on to lithium, in patients with a first episode of psychotic mania, expecting better safety profile and adherence to olanzapine but similar efficacy for both treatments.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">Data from 83 patients were collected in an 8-week randomised controlled trial on clinical variables, side effects, vital signs, and weight. Analyses of treatment differences over time were based on intent-to-treat principles. Kaplan-Meier estimated survival curves were used to analyse time-to-event data and mixed effects models repeated measures analysis of variance were used to determine treatment group differences over time on safety and efficacy measures.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">Ethics committee approval to delay informed consent procedure until recovery from the acute episode allowed the inclusion of 83 patients highly representative of those treated in the public sector. Contrary to our hypotheses, safety profile of both medications was similar. A signal for higher rate (P=.032) and earlier occurrence (P=.043) of mania remission was observed in the olanzapine group which did not survive correction for multiple comparisons.</AbstractText>
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Olanzapine and chlorpromazine have a similar safety profile in a uniquely representative cohort of patients with first episode psychotic mania. The possibility for a greater impact of olanzapine on manic symptoms leading to earlier remission of the episode needs exploration in a large sample.</AbstractText>
<CopyrightInformation>Copyright © 2015 Elsevier Masson SAS. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Conus</LastName>
<ForeName>P</ForeName>
<Initials>P</Initials>
<AffiliationInfo><Affiliation>Treatment and Early Intervention in Psychosis Program (TIPP), département de psychiatrie CHUV, université de Lausanne, clinique de Cery, 1008 Prilly, Switzerland; Orygen Youth Health Research Centre, Centre for Youth Mental Health, University of Melbourne, 35 Poplar Road, Parkville Victoria 3052, Melbourne, Australia. Electronic address: philippe.conus@chuv.ch.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Berk</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>Orygen Youth Health Research Centre, Centre for Youth Mental Health, University of Melbourne, 35 Poplar Road, Parkville Victoria 3052, Melbourne, Australia; Department of Clinical and Biomedical Sciences, Barwon Health, University of Melbourne, Geelong, Australia; Mental Health Research Institute, Parkville, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Cotton</LastName>
<ForeName>S M</ForeName>
<Initials>SM</Initials>
<AffiliationInfo><Affiliation>Orygen Youth Health Research Centre, Centre for Youth Mental Health, University of Melbourne, 35 Poplar Road, Parkville Victoria 3052, Melbourne, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Kader</LastName>
<ForeName>L</ForeName>
<Initials>L</Initials>
<AffiliationInfo><Affiliation>Orygen Youth Health Research Centre, Centre for Youth Mental Health, University of Melbourne, 35 Poplar Road, Parkville Victoria 3052, Melbourne, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Macneil</LastName>
<ForeName>C</ForeName>
<Initials>C</Initials>
<AffiliationInfo><Affiliation>Orygen Youth Health Research Centre, Centre for Youth Mental Health, University of Melbourne, 35 Poplar Road, Parkville Victoria 3052, Melbourne, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Hasty</LastName>
<ForeName>M K</ForeName>
<Initials>MK</Initials>
<AffiliationInfo><Affiliation>Orygen Youth Health Research Centre, Centre for Youth Mental Health, University of Melbourne, 35 Poplar Road, Parkville Victoria 3052, Melbourne, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Hallam</LastName>
<ForeName>K</ForeName>
<Initials>K</Initials>
<AffiliationInfo><Affiliation>Orygen Youth Health Research Centre, Centre for Youth Mental Health, University of Melbourne, 35 Poplar Road, Parkville Victoria 3052, Melbourne, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Lambert</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>Department for Psychiatry and Psychotherapy, Psychosis Early Detection and Intervention Centre (PEDIC), Centre for Psychosocial Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Murphy</LastName>
<ForeName>B P</ForeName>
<Initials>BP</Initials>
<AffiliationInfo><Affiliation>Faculty of Medicine, Nursing and Health Sciences, School of Psychology, Psychiatry and Psychological Medicine, Monash University, Victoria 3800, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>McGorry</LastName>
<ForeName>P D</ForeName>
<Initials>PD</Initials>
<AffiliationInfo><Affiliation>Orygen Youth Health Research Centre, Centre for Youth Mental Health, University of Melbourne, 35 Poplar Road, Parkville Victoria 3052, Melbourne, Australia.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2015</Year>
<Month>10</Month>
<Day>21</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>England</Country>
<MedlineTA>Eur Psychiatry</MedlineTA>
<NlmUniqueID>9111820</NlmUniqueID>
<ISSNLinking>0924-9338</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>12794-10-4</RegistryNumber>
<NameOfSubstance UI="D001569">Benzodiazepines</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>9FN79X2M3F</RegistryNumber>
<NameOfSubstance UI="D008094">Lithium</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>N7U69T4SZR</RegistryNumber>
<NameOfSubstance UI="D000077152">Olanzapine</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>U42B7VYA4P</RegistryNumber>
<NameOfSubstance UI="D002746">Chlorpromazine</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D001569" MajorTopicYN="Y">Benzodiazepines</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName>
<QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
<QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002746" MajorTopicYN="Y">Chlorpromazine</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D039721" MajorTopicYN="N">Diagnostic and Statistical Manual of Mental Disorders</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016903" MajorTopicYN="N">Drug Monitoring</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008094" MajorTopicYN="N">Lithium</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000077152" MajorTopicYN="N">Olanzapine</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Antipsychotic treatment</Keyword>
<Keyword MajorTopicYN="N">Bipolar disorder</Keyword>
<Keyword MajorTopicYN="N">First episode</Keyword>
<Keyword MajorTopicYN="N">Mania</Keyword>
<Keyword MajorTopicYN="N">Psychosis</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year>
<Month>06</Month>
<Day>23</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised"><Year>2015</Year>
<Month>09</Month>
<Day>13</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2015</Year>
<Month>09</Month>
<Day>14</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2015</Year>
<Month>10</Month>
<Day>21</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2015</Year>
<Month>10</Month>
<Day>21</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2016</Year>
<Month>6</Month>
<Day>28</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">26485297</ArticleId>
<ArticleId IdType="pii">S0924-9338(15)00179-0</ArticleId>
<ArticleId IdType="doi">10.1016/j.eurpsy.2015.09.009</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>Allemagne</li>
<li>Australie</li>
</country>
<region><li>Hambourg</li>
<li>Victoria (État)</li>
</region>
<settlement><li>Hambourg</li>
<li>Melbourne</li>
</settlement>
<orgName><li>Université de Melbourne</li>
</orgName>
</list>
<tree><country name="Australie"><region name="Victoria (État)"><name sortKey="Conus, P" sort="Conus, P" uniqKey="Conus P" first="P" last="Conus">P. Conus</name>
</region>
<name sortKey="Berk, M" sort="Berk, M" uniqKey="Berk M" first="M" last="Berk">M. Berk</name>
<name sortKey="Cotton, S M" sort="Cotton, S M" uniqKey="Cotton S" first="S M" last="Cotton">S M Cotton</name>
<name sortKey="Hallam, K" sort="Hallam, K" uniqKey="Hallam K" first="K" last="Hallam">K. Hallam</name>
<name sortKey="Hasty, M K" sort="Hasty, M K" uniqKey="Hasty M" first="M K" last="Hasty">M K Hasty</name>
<name sortKey="Kader, L" sort="Kader, L" uniqKey="Kader L" first="L" last="Kader">L. Kader</name>
<name sortKey="Macneil, C" sort="Macneil, C" uniqKey="Macneil C" first="C" last="Macneil">C. Macneil</name>
<name sortKey="Mcgorry, P D" sort="Mcgorry, P D" uniqKey="Mcgorry P" first="P D" last="Mcgorry">P D Mcgorry</name>
<name sortKey="Murphy, B P" sort="Murphy, B P" uniqKey="Murphy B" first="B P" last="Murphy">B P Murphy</name>
</country>
<country name="Allemagne"><region name="Hambourg"><name sortKey="Lambert, M" sort="Lambert, M" uniqKey="Lambert M" first="M" last="Lambert">M. Lambert</name>
</region>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Bois/explor/PoplarV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001C19 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001C19 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Bois
   |area=    PoplarV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:26485297
   |texte=   Olanzapine or chlorpromazine plus lithium in first episode psychotic mania: An 8-week randomised controlled trial.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:26485297" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a PoplarV1

This area was generated with Dilib version V0.6.37.
Data generation: Wed Nov 18 12:07:19 2020. Site generation: Wed Nov 18 12:16:31 2020

	Serveur d'exploration sur le peuplier
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur le peuplier

Olanzapine or chlorpromazine plus lithium in first episode psychotic mania: An 8-week randomised controlled trial.

Olanzapine or chlorpromazine plus lithium in first episode psychotic mania: An 8-week randomised controlled trial.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki